Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $68.00 | Total: $340.00 |
| 1 | 10 | $57.60 | Total: $576.00 |
| 1 | 25 | $48.80 | Total: $1,220.00 |
| 1 | 50 | $41.60 | Total: $2,080.00 |
| 1 | 100 | $36.00 | Total: $3,600.00 |
Overview
Abeprazan hydrochloride (Fexuprazan hydrochloride) is an effective reversible potassium-competitive acid blocker with oral activity, inhibiting H+, K+ -atPase by competitive binding to potassium ions without acid activation. Abeprazan hydrochloride is a proton pump inhibitor (PPI) that acts by reducing gastric acid production and is used to treat gastric acid-related disorders, such as gastroesophageal reflux disease (GERD) and peptic ulcers.
Chemical Properties
| Molecular Formula | C19H18ClF3N2O3S |
| Molecular Weight | 446.87 |
| CAS Numbers | 1902954-87-3 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | Cl.CNCc1cn(c(c1OC)-c1ccc(F)cc1F)S(=O)(=O)c1cccc(F)c1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Sunwoo J, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2018 Jul;48[2] 206-218.